Cell Therapies for Atrophic AMD

Related

• 

  Association Between Dysfunctional Complement Factor I: Rare Variant Status and Progression to Advanced AMD Outcomes

  Johanna M. Seddon, MD, ScM, FARVO, FASRS

  Annual Meeting Talks

  2022

• 

  Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study

  W. Lloyd Clark, MD, FASRS

  Updates from the Field

  2022

• 

  Expert Panel: Pegcetacoplan Safety

  Andre J. Witkin, MD

  David A. Eichenbaum, MD, FASRS

  Samuel Anthony Minaker, MD, MSc

  Janani Singaravelu, MS, MD

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2024